Document Detail

Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study.
MedLine Citation:
PMID:  20719465     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: General recommendations indicate that, during a carotid artery stenting (CAS), sufficient unfractionated heparin (UFH) has to be given to maintain the activated clotting time between 250 to 300 seconds. Bivalirudin use is able to reduce postprocedural bleedings in percutaneous interventions when compared with UFH. The study purpose was to evaluate, in a randomized study, the safety and efficacy of bivalirudin versus heparin during CAS, using proximal endovascular occlusion (PEO) as a distal protection device.
METHODS: From January 2006 to December 2009, 220 patients undergoing CAS using PEO have been randomly assigned to one of the study arms (control arm: 100 UI/kg UFH or bivalirudin arm: 0.75 mg/kg intravenous bolus and intraprocedural infusion at 1.75 mg/kg/h).
RESULTS: Procedural success was achieved in all the patients. No episodes of intraprocedural thrombosis occurred. One major stroke occurred in the bivalirudin arm, and two minor strokes occurred, one in each group. A significant difference in the incidence of postprocedural bleedings was observed between the study groups; bivalirudin use was associated with reduced number of bleedings according to Thrombolysis In Myocardial Infarction criteria.
CONCLUSIONS: The use of bivalirudin should be considered a safe and effective anticoagulation regimen during CAS, using PEO as a distal protection device. Bivalirudin use is associated with a reduced incidence of bleedings.
Eugenio Stabile; Giovanni Sorropago; Tullio Tesorio; Grigore Popusoi; Vittorio Ambrosini; Maria Teresa Mottola; Giancarlo Biamino; Paolo Rubino
Related Documents :
9126125 - A short course of low-molecular-weight heparin to prevent deep venous thrombosis after ...
2539025 - Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergota...
2463035 - Thrombosis prophylaxis with low molecular weight heparin in total hip replacement.
8616945 - Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vei...
12071065 - Predictors of mortality in brain abscess.
9828235 - Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic h...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2010-08-17
Journal Detail:
Title:  Journal of vascular surgery     Volume:  52     ISSN:  1097-6809     ISO Abbreviation:  J. Vasc. Surg.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-14     Completed Date:  2011-04-06     Revised Date:  2012-10-03    
Medline Journal Info:
Nlm Unique ID:  8407742     Medline TA:  J Vasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1505-10     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.
Invasive Cardiology Laboratory, Cardiology Division, Clinica Montevergine, Mercogliano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / therapeutic use*
Balloon Occlusion*
Blood Loss, Surgical / prevention & control
Carotid Artery, Internal*
Carotid Stenosis / surgery*
Endovascular Procedures*
Heparin / therapeutic use*
Peptide Fragments / therapeutic use*
Recombinant Proteins / therapeutic use
Stroke / prevention & control*
Thrombosis / prevention & control
Whole Blood Coagulation Time
Reg. No./Substance:
0/Anticoagulants; 0/Hirudins; 0/Peptide Fragments; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A nationwide survey of standardized patients: Who they are, what they do, and how they experience th...
Next Document:  Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques.